Prognostic Value of [99mTc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and Preserved Left Ventricular Function.

Caobelli, Federico; Gözlügöl, Nasir; Bakula, Adam; Rominger, Axel; Schepers, Robin; Stortecky, Stefan; Hunziker Munsch, Lukas; Dobner, Stephan; Gräni, Christoph (2024). Prognostic Value of [99mTc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and Preserved Left Ventricular Function. (In Press). Journal of nuclear medicine Society of Nuclear Medicine and Molecular Imaging 10.2967/jnumed.123.266926

[img] Text
jnumed.123.266926.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (693kB) | Request a copy

Quantitative 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid ([99mTc]Tc-DPD) SPECT may be used for risk-stratifying patients with amyloid transthyretin-related cardiomyopathy (ATTR-CM). We aimed to analyze the predictive value of quantitative [99mTc]Tc-DPD SPECT/CT in suspected and confirmed ATTR-CM according to different disease stages. Methods: The study enrolled consecutive patients with suspected ATTR-CM who were referred to a single tertiary center and underwent quantitative [99mTc]Tc-DPD SPECT/CT allowing SUVmax and SUVpeak analysis. Patients were divided into 2 groups according to left ventricular ejection fraction (LVEF) at baseline (i.e., ≥50% and <50%). Clinical, laboratory, and echocardiographic parameters and major adverse cardiac events (i.e., all-cause death, sustained ventricular tachyarrhythmia, hospitalization for heart failure, implantation of a cardioverter defibrillator) were investigated for any correlation with quantitative uptake values. Results: In total, 144 patients with suspected ATTR-CM were included in the study (98 with LVEF ≥ 50% and 46 with LVEF < 50%), of whom 99 were diagnosed with ATTR-CM (68.8%; 69 with LVEF ≥ 50% and 30 with LVEF < 50%). A myocardial SUVmax of at least 7 was predictive of major adverse cardiac events at 21.9 ± 13.0 mo of follow-up (hazard ratio, 2.875; 95% CI, 1.23-6.71; P = 0.015) in patients with suspected or confirmed ATTR-CM (global χ2 = 6.892, P = 0.02) and an LVEF of at least 50%. SUVmax was not predictive in patients with an LVEF of less than 50% and suspected or confirmed ATTR-CM. Conclusion: In patients with suspected or confirmed ATTR-CM and preserved LVEF, representing an early disease stage, quantitative [99mTc]Tc-DPD SPECT should be considered to improve early-stage risk stratification.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Caobelli, Federico, Gözlügöl, Nasir, Bakula, Adam, Rominger, Axel Oliver, Schepers, Robin Antoon, Stortecky, Stefan, Hunziker Munsch, Lukas Christoph, Dobner, Stephan, Gräni, Christoph

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1535-5667

Publisher:

Society of Nuclear Medicine and Molecular Imaging

Language:

English

Submitter:

Pubmed Import

Date Deposited:

13 May 2024 14:21

Last Modified:

13 May 2024 14:30

Publisher DOI:

10.2967/jnumed.123.266926

PubMed ID:

38724281

Uncontrolled Keywords:

ATTR ATTR-CM DPD SPECT cardiac transthyretin amyloidosis quantitative SPECT

BORIS DOI:

10.48350/196675

URI:

https://boris.unibe.ch/id/eprint/196675

Actions (login required)

Edit item Edit item
Provide Feedback